Shares of Adient plc (NYSE:ADNT – Get Free Report) have received a consensus rating of “Hold” from the eight research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $39.25.
Several analysts recently weighed in on the company. Morgan Stanley decreased their target price on Adient from $35.00 to $32.00 and set an “underweight” rating for the company in a research note on Friday, May 10th. Deutsche Bank Aktiengesellschaft decreased their target price on Adient from $32.00 to $30.00 and set a “hold” rating for the company in a research note on Monday, May 6th. Barclays decreased their target price on Adient from $37.00 to $34.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 7th. Wells Fargo & Company decreased their target price on Adient from $38.00 to $33.00 and set an “overweight” rating for the company in a research note on Monday, May 6th. Finally, Bank of America decreased their target price on Adient from $50.00 to $46.00 and set a “buy” rating for the company in a research note on Wednesday, April 10th.
Check Out Our Latest Analysis on Adient
Insider Buying and Selling at Adient
Hedge Funds Weigh In On Adient
A number of hedge funds have recently modified their holdings of ADNT. Boston Partners increased its holdings in Adient by 12.2% during the 1st quarter. Boston Partners now owns 19,661 shares of the company’s stock valued at $647,000 after purchasing an additional 2,139 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Adient by 48.5% during the 1st quarter. Janus Henderson Group PLC now owns 697,303 shares of the company’s stock valued at $22,955,000 after purchasing an additional 227,810 shares in the last quarter. Bayesian Capital Management LP acquired a new stake in Adient during the 1st quarter valued at $316,000. Price T Rowe Associates Inc. MD increased its holdings in Adient by 5.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 56,647 shares of the company’s stock valued at $1,865,000 after purchasing an additional 2,687 shares in the last quarter. Finally, Magnetar Financial LLC acquired a new stake in Adient during the 1st quarter valued at $2,746,000. 92.44% of the stock is owned by institutional investors and hedge funds.
Adient Stock Performance
ADNT opened at $25.44 on Friday. The company has a market cap of $2.29 billion, a PE ratio of 15.61, a price-to-earnings-growth ratio of 0.35 and a beta of 2.31. The stock has a 50-day moving average of $28.11 and a 200-day moving average of $31.93. Adient has a 52-week low of $24.90 and a 52-week high of $46.51. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.91 and a current ratio of 1.13.
Adient (NYSE:ADNT – Get Free Report) last released its quarterly earnings results on Friday, May 3rd. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.15. The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.80 billion. Adient had a return on equity of 8.72% and a net margin of 1.04%. The firm’s revenue was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.32 EPS. As a group, equities research analysts forecast that Adient will post 2.23 earnings per share for the current fiscal year.
About Adient
Adient plc engages in the design, development, manufacture, and market of seating systems and components for passenger cars, commercial vehicles, and light trucks. The company's automotive seating solutions include complete seating systems, frames, mechanisms, foams, head restraints, armrests, and trim covers.
Further Reading
- Five stocks we like better than Adient
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Sarepta Therapeutics Stock Soars on FDA Approval
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- CarMax: A Market Melt-Up Waiting to Happen for this Stock
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 Solar Stocks to Watch that are Building the Green Energy Future
Receive News & Ratings for Adient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adient and related companies with MarketBeat.com's FREE daily email newsletter.